• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.

作者信息

Rowland Yeo Karen, Gil Berglund Eva

机构信息

Certara UK Limited (Simcyp Division), Sheffield, UK.

Certara Integrated Drug Development, Oss, The Netherlands.

出版信息

Clin Pharmacol Ther. 2021 Nov;110(5):1168-1171. doi: 10.1002/cpt.2243. Epub 2021 May 2.

DOI:10.1002/cpt.2243
PMID:33934342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8596427/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10da/8596427/0efd65fa2876/CPT-110-1168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10da/8596427/67c416972511/CPT-110-1168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10da/8596427/0efd65fa2876/CPT-110-1168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10da/8596427/67c416972511/CPT-110-1168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10da/8596427/0efd65fa2876/CPT-110-1168-g001.jpg

相似文献

1
An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.一种评估肾功能损害对研发中药物药代动力学影响的综合方法：生理药代动力学（PBPK）建模的关键作用
Clin Pharmacol Ther. 2021 Nov;110(5):1168-1171. doi: 10.1002/cpt.2243. Epub 2021 May 2.
2
Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics.预测儿科药物处置——儿科生理药代动力学的现状与未来方向
Drug Metab Lett. 2015;9(2):80-7. doi: 10.2174/1872312809666150602151429.
3
Toxicology Strategies for Drug Discovery - Present and Future: Introduction.药物发现的毒理学策略：现状与未来：引言
Chem Res Toxicol. 2016 Apr 18;29(4):437. doi: 10.1021/acs.chemrestox.6b00049.
4
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.在药物吸收、分布、代谢、排泄和毒性的基于生理的药代动力学模型的保护伞下，探讨生理 pH 值和化学 pKa 的相互作用。
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1103-1124. doi: 10.1080/17425255.2021.1951223. Epub 2021 Jul 31.
5
[FOOD - DRUG INTERACTIONS: TYPES AND MECHANISMS.].
Eksp Klin Farmakol. 2016;79(11):41-44.
6
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.在药物开发和监管应用的 PBPK 建模中纳入溶出数据的现状和未来机遇：OrBiTo 联盟评论。
Eur J Pharm Biopharm. 2020 Oct;155:55-68. doi: 10.1016/j.ejpb.2020.08.005. Epub 2020 Aug 8.
7
Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.基于 PBPK 模型的剂量优化：现状与未来。
Clin Pharmacol Ther. 2024 Sep;116(3):563-576. doi: 10.1002/cpt.3289. Epub 2024 Apr 30.
8
Predicting Food Effects: Are We There Yet?预测食物效应：我们做到了吗？
AAPS J. 2022 Jan 10;24(1):25. doi: 10.1208/s12248-021-00674-x.
9
A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development.应用基于生理学的药代动力学模型进行儿科药物开发的最佳实践框架。
CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):967-972. doi: 10.1002/psp4.12678. Epub 2021 Jul 20.
10
Physiologically based pharmacokinetic modeling in obesity: applications and challenges.肥胖人群的生理基础药代动力学模型：应用与挑战。
Expert Opin Drug Metab Toxicol. 2024 Aug;20(8):805-816. doi: 10.1080/17425255.2024.2388690. Epub 2024 Aug 12.

引用本文的文献

1
Development of PBPK Population Model for End-Stage Renal Disease Patients to Inform OATP1B-, BCRP-, P-gp-, and CYP3A4-Mediated Drug Disposition with Individual Influencing Factors.用于终末期肾病患者的PBPK群体模型的开发，以了解OATP1B、BCRP、P-糖蛋白和CYP3A4介导的药物处置及个体影响因素。
Pharmaceutics. 2025 Aug 20;17(8):1078. doi: 10.3390/pharmaceutics17081078.
2
Predicting drug-drug interactions and optimal dosing of betrixaban with physiologically based pharmacokinetic modeling in patients with renal impairment who were coadministered with P-glycoprotein inhibitors.在合并使用P-糖蛋白抑制剂的肾功能不全患者中，通过基于生理的药代动力学模型预测贝曲西班的药物相互作用和最佳剂量。
J Int Med Res. 2025 Jun;53(6):3000605251346587. doi: 10.1177/03000605251346587. Epub 2025 Jun 6.
3

本文引用的文献

1
Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.基于生理的药代动力学模型在预测联合给予奥氮平和氨丁三醇时肾功能损害对其药代动力学影响中的应用。
Clin Pharmacokinet. 2021 May;60(5):637-647. doi: 10.1007/s40262-020-00969-w. Epub 2020 Dec 14.
2
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.生理药代动力学模型在肾功能和肝功能损伤人群中的应用：制药行业视角。
Clin Pharmacol Ther. 2021 Aug;110(2):297-310. doi: 10.1002/cpt.2125. Epub 2020 Dec 30.
3
Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function.肾功能受损患者头孢噻肟的生理药代动力学模型
Clin Pharmacokinet. 2025 Feb;64(2):257-273. doi: 10.1007/s40262-024-01469-x. Epub 2025 Jan 7.
4
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach.模拟健康受试者的药代动力学用于肾和肝损伤研究：方法的回顾性评估。
AAPS J. 2024 Jun 6;26(4):65. doi: 10.1208/s12248-024-00928-4.
5
Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.替皮法尼布基于生理学的药代动力学模型，以评估健康受试者和癌症患者中的药物相互作用、器官损伤和生物药剂学。
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1366-1379. doi: 10.1002/psp4.13165. Epub 2024 May 28.
6
The Role of "Physiologically Based Pharmacokinetic Model (PBPK)" New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment.“生理药代动力学模型 (PBPK)”新方法学 (NAM) 在药品和环境化学风险评估中的作用。
Int J Environ Res Public Health. 2023 Feb 16;20(4):3473. doi: 10.3390/ijerph20043473.
Physiologically-Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study.
基于生理的药代动力学模型在药物研发中实现精准给药的作用：人体质量平衡研究的关键作用
Clin Pharmacol Ther. 2021 Jan;109(1):51-54. doi: 10.1002/cpt.2092. Epub 2020 Nov 21.
4
A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions.2010年至2015年初美国新肿瘤药物获批的肾功能损害药代动力学研究调查：聚焦于开发策略与未来方向
Anticancer Drugs. 2017 Aug;28(7):677-701. doi: 10.1097/CAD.0000000000000513.
5
Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.基于生理的药代动力学模型在理解博舒替尼药代动力学中的应用：药物-药物和药物-疾病相互作用的预测
Drug Metab Dispos. 2017 Apr;45(4):390-398. doi: 10.1124/dmd.116.074450. Epub 2017 Feb 6.
6
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.在药物审查过程中，利用基于生理学的药代动力学（PBPK）建模方法定量预测利伐沙班复杂的药物-药物-疾病相互作用场景的实用性：对临床实践的影响。
Biopharm Drug Dispos. 2012 Mar;33(2):99-110. doi: 10.1002/bdd.1771. Epub 2012 Mar 4.